Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :A compound harvested from soft coral off the coast of Taiwan could pro.. 2009-09-05 18:54:20 
Harrison
Newbie
Joined: 2009-07-13 23:53:04
Posts: 31
Location
  • 4294967292
Subject :A compound harvested from soft coral off the coast of Taiwan could provide a new treatment for pain

 

Ocean coral 'offers pain therapy'


A compound harvested from soft coral off the coast of Taiwan could provide a new treatment for pain from intractable nerve damage, experts say.

 

Traditional painkillers like aspirin and even morphine often do little to take the edge off neuropathic pain.

 

But research in the British Journal of Pharmacology suggests Capnella imbricata, or Kenya Tree Coral, could provide relief.

 

The Taiwanese scientists report promising early trial results in rats.

Several important drugs have already been developed from chemicals found in coral reef organisms.

 

Among these is the antiviral AZT, a treatment for people with HIV, which is based on chemicals extracted from a Caribbean reef sponge.

 

Reefs have also yielded treatments for cardiovascular diseases, ulcers, leukaemia and skin cancer.

 

Deep treasures

Dr Zhi-Hong Wen and colleagues at the National Sun Yat-Sen University have been testing a chemical called capnellene, which is isolated from soft coral collected at Green Island, a small volcanic island in the Pacific Ocean about 33km off the eastern coast of Taiwan.

The reef there is said to be home to more than 200 different types of coral.

 

Capnellene appears to work on the supporting cells that surround nerve cells, which are thought to be responsible for neuropathic pain in some way.

 

Recent research suggests inflammation plays a role, and inflammation activates supporting cells like microglia to release compounds that can excite nerves carrying pain signals.

 

People with neuropathic pain experience severe pain from a stimulus or touch that would normally cause only slight discomfort or stimuli that would normally induce no pain at all.

 

Some even get unpleasant or painful feelings even when there is no stimulus.

It is estimated that about 1 in 100 people in the UK have persistent neuropathic pain - many are people with nerve damage caused by diabetes.

 

Dr Wen's team tested capnellene and a second very similar compound in isolated microglia cells and in experimental models of neuropathic pain in rats, with promising results.

 

They say more studies are now needed to see if this could offer a new way to treat the condition.

 

Dr Wen said: "Today there are few pharmacological agents that can help people suffering from neuropathic pain, but we believe that these marine-derived compounds could lead to the development of a new range of drugs of great potential."       

 

 

Source: BBC News                                                                

 

IP Logged
Page # 


Powered by ccBoard